Different outcomes for relapsed versus refractory neuroblastoma after therapy with I-131-metaiodobenzylguanidine (I-131-MIBG)

摘要

Background: I-131-metaiodobenzylguanidine (I-131-MIBG) is a targeted radiopharmaceutical with significant activity in high-risk relapsed and chemotherapy-refractory neuroblastoma. Our primary aim was to determine if there are differences in response rates to I-131-MIBG between patients with relapsed and treatment-refractory neuroblastoma.